Leveraging drug rebates for medical stop loss product innovation

Rising drug costs present new challenges for medical stop loss (MSL) insurers. As costs increase, drugs and associated rebates present an opportunity for product innovation. This paper by Milliman’s Kevin Pierce and Thomas Murawski explores potential innovations and key strategies for MSL insurers.

Leave a Reply

Your email address will not be published. Required fields are marked *